文献速递妇科

复发性卵巢癌患者寡转移进展后局部治疗联合PARP抑制剂延长的研究

PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients.
PubMed 文献 · Gynecol Oncol · 2023-04-25

这项国际多中心回顾性研究评估了74例高级别上皮性卵巢癌患者在局部治疗寡转移进展后继续或重新引入PARP抑制剂的疗效,中位无进展生存期为11.5个月,1年总生存率为90.7%,6例(8.1%)因毒性停药,提示该策略可行且可能获益。

要点

  • 74例患者中65%存在BRCA突变,92%在首次使用PARP抑制剂前接受过≥2线系统化疗。
  • 局部治疗后PARP抑制剂中位无进展生存期为11.5个月(95%CI 7.4-17.2)。
  • 中位随访14.8个月,6例(8.1%)因毒性停用PARP抑制剂,1年总生存率90.7%。

核心结论

  • 在PARP抑制剂治疗期间出现寡转移进展的患者中,局部治疗后继续或重新引入PARP抑制剂可行且可能获益,接近一年未进展或未开始新线系统治疗。

研究设计与样本

  • 国际多中心回顾性研究,纳入20个中心2020年4月至2021年11月间74例高级别上皮性卵巢癌患者,评估局部治疗后PARP抑制剂的无进展生存期、安全性和总生存期。

主要发现

  • 74例患者中65%为BRCA突变,92%在首次引入PARP抑制剂前已接受≥2线系统化疗。
  • 主要进展部位为淋巴结(42%)、腹膜(27%)、肝脏(16%)、其他内脏(16%)和腹壁(4%)。
  • 局部治疗包括放疗(45%)、手术(43%)、两者联合(7%)、经皮热消融(4%)或化疗栓塞(1%)。
  • 局部治疗后PARP抑制剂中位无进展生存期为11.5个月(95%CI 7.4-17.2)。
  • 中位随访14.8个月后,6例(8.1%)因毒性停用PARP抑制剂,1年总生存率为90.7%(95%CI 79.1-96.0)。

临床怎么用

  • 作者认为,对于PARP抑制剂治疗中出现寡转移进展的患者,局部治疗后继续或重新引入PARP抑制剂是可行的且可能获益。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: PARP inhibitors (PARPi) have revolutionized the management of high-grade epithelial ovarian cancer (HGOC) treatment. However, a significant number of patients relapse or progress under PARPi, leading to the introduction of a new line of systemic therapy such as chemotherapy. In patients with a limited number of metastatic sites at progression, -referred to as an oligometastatic progression- a potential indication for local therapy followed by re-introduction or continuation of PARPi treatment rather than initiating a new line of chemotherapy could be proposed. However, the impact of such strategies on progression free survival (PFS) in these patients remains unknown. METHODS: This international multicenter retrospective study evaluated the efficacy of PARPi continuation or re-introduction in patients with HGOC after local treatment for oligometastatic progression. The main objective was to assess PFS under PARPi after local therapy (PFS post-LT). Secondary objectives included safety and overall survival (OS). RESULTS: 74 patients were identified in 20 centers between April 2020 and November 2021. 65% of patients were BRCA mutated and 92% had received ≥2 lines of prior systemic chemotherapy before the initial introduction of PARPi. Main progression sites were lymph nodes (42%), peritoneum (27%), liver (16%), other visceral (16%) and abdominal wall (4%). Local therapies included radiotherapy (45%), surgery (43%), both (7%), percutaneous thermal ablation (4%) or chemoembolization (1%). Median PFS post-LT was 11.5 months [95% CI 7.4; 17.2]. After a median follow up of 14.8 months, 6 patients (8.1%) discontinued PARPi due to toxicity. The 1-year overall survival rate was 90.7% [95% CI 79.1; 96.0]. CONCLUSIONS: With close to one year without progression or introduction of a new line of systemic therapy, this study reports the feasibility and potential benefit of this original strategy in patients with oligometastatic progression under PARPi.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Gauduchon T, Kfoury M, Lorusso D, et al. PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients. Gynecol Oncol. 2023. PMID: 37105063. doi:10.1016/j.ygyno.2023.04.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。